Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7204239 versus placebo in adults with facioscapulohumeral muscular dystrophy
2022-503117-36-00Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in facioscapulohumeral muscular dystrophy (FSHD) comparing RO7204239 with Placebo (2 arms). Primary endpoints: Percent change from baseline in contractile muscle volume of quadriceps femoris muscles, Adverse events and 6 more. Started Dec 2022; status: completed.
02
Drugs
emugrobart
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on 2022-503117-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503117-36-00.